Introduction
Lung cancer is the leading cause of cancer-related deaths in men and women worldwide. The incidence of lung cancer in women has increased even faster than the overall incidence, reflecting their increased use of tobacco in the past 30 years. Most patients present with advanced stage IIIB or IV disease. CT screening can detect most cases of lung cancer. Over 80% of all the diagnoses are of stage I, with a potentially high curability rate of more than 90%.1,2,3
Image of a 1.8-cm peripheral carcinoma in the lingula, stage T1.
Right middle lobe peripheral carcinoma, 3.5 cm in diameter, stage T2.
Right apical carcinoma, stage T3.
Right hilar mass invading the mediastinum, stage T4, with mediastinal lymphadenopathy, N3 (see Images 16-19 in Multimedia).
The most important prognostic indicator in lung cancer is the extent of disease. The Union Internationale Contre le Cancer (UICC) and the American Joint Committee for Cancer Staging (AJCC) have developed the tumor, node, and metastases (TNM) staging system, which takes into account the degree of spread of the primary tumor, the extent of regional lymph node involvement, and the presence or absence of distant metastases.
Non–small cell lung cancer (NSCLC) accounts for approximately 75% of all lung cancers. NSCLC is subdivided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Despite their histologic and clinical differences, they share a similar prognosis and management and are staged by using the same TNM system.
Surgery is the treatment of choice for NSCLC if the primary tumor is resectable and if metastatic disease is absent. Chemotherapy and radiation therapy are used to treat tumors that are unresectable because of intrathoracic spread or distant metastases. Small cell lung cancer (SCLC), which metastasizes early and has a worse outcome than NSCLC, has a separate staging system (see Staging of SCLC).
For excellent patient education resources, visit eMedicine's Cancer and Tumors Center. Also, see eMedicine's patient education articles Lung Cancer, Understanding Lung Cancer Medications, and Non-Small-Cell Lung Cancer.
TNM Staging
The stages represent the nature and extent of spread of a neoplasm and, thus, the therapeutic options and prognosis in individual patients. Stages also provide a standard by which various therapies can be compared. A combination of clinical, laboratory, radiologic, and pathologic investigations are used to stage various neoplasms.4,5
Different staging systems have been developed. The most widely used scheme for staging NSCLC is the TNM classification. The UICC and the AJCC initially introduced this system in 1972 with staging and end-results reporting. This scheme has been modified and refined over the years. The TNM classification in the publications of the UICC and the AJCC are identical. They were formulated together but appear in separate books—namely, the UICC TNM Classification of Malignant Tumors6 and the AJCC Cancer Staging Manual.7
TNM is a dual system with a pretreatment Clinical classification (cTNM or TNM) and a postsurgical histopathologic Pathological classification (pTNM). Both classifications are retained unaltered in the patient's record. The former is used for the choice of treatment; the latter is used for the estimation of prognosis and the possible selection of adjuvant therapy.
The TNM staging system takes into account the degree of spread of the primary tumor, represented by T; the extent of regional lymph node involvement, represented by N; and the presence or absence of distant metastases, represented by M. The TNM system is used for all lung carcinomas except SCLCs, which are staged separately (see Staging of SCLC).
Image of a 1.8-cm peripheral carcinoma in the lingula, stage T1.
Spiculated right upper lobe carcinoma, 4.2 cm in diameter, stage T2.
Right apical carcinoma, stage T3.
The left hilar tumor extends to the carina, invades the left pulmonary artery, and is contiguous with the descending aorta over an arc of greater than 180° the stage is T4. The primary tumor is difficult to separate from the mediastinal lymphadenopathy (stage Nx) and from the distal atelectasis and pneumonitis.
In the TNM systems, 4 stages are further subdivided into I-III and A or B subtypes. These stages have important therapeutic and prognostic implications. The stages are as follows:
- Primary tumor
- Tis - Carcinoma in situ
- TX - Positive malignant cytologic findings, no lesion observed
- T1 - Diameter of 3 cm or smaller and surrounded by lung or visceral pleura (see Image 1) or endobronchial tumor distal to the lobar bronchus
- T2 -Diameter greater than 3 cm (see Images 2-3); extension to the visceral pleura, atelectasis, or obstructive pneumopathy involving less than 1 lung; lobar endobronchial tumor; or tumor of a main bronchus more than 2 cm from the carina
- T3 - Tumor at the apex (see Image 5); total atelectasis of 1 lung; endobronchial tumor of main bronchus within 2 cm of the carina but not invading it; or tumor of any size with direct extension to the adjacent structures such as the chest wall mediastinal pleura (see Image 8), diaphragm, pericardium parietal layer, or mediastinal fat of the phrenic nerve
- T4 - Invasion of the mediastinal organs, including the esophagus trachea, carina (see Image 11), great vessels (see Image 13), and/or heart; obstruction of the superior vena cava; involvement of a vertebral body; recurrent nerve involvement; malignant pleural or pericardial effusion; or satellite pulmonary nodules within the same lobe as the primary tumor
- Regional lymph node involvement
- N0 - No lymph nodes involved
- N1 - Ipsilateral bronchopulmonary or hilar nodes involved
- N2 - Ipsilateral mediastinal nodes or ligament involved
- Upper paratracheal lower paratracheal nodes
- Pretracheal (see Image 4, Image 7, Image 10) and retrotracheal nodes
- Aortic and aortic window nodes
- Para-aortic nodes
- Para-esophageal nodes
- Pulmonary ligament
- Subcarinal nodes (see Images 12-17)
- N3 - contralateral mediastinal or hilar nodes involved (see Image 19) or any scalene or supraclavicular nodes involved
- Metastatic involvement
- M0 - No metastases
- M1 - Metastases present (see Images 20-27)
Liver metastases of lung cancer.
Stage groupings are as follows:
- IA - T1N0M0
- IB - T2N0M0
- IIA - T1N1M0
- IIB - T2N1M0 or T3N0M0
- IIIA - T1-3N2M0 or T3N1M0
- IIIB - Any T4 or any N3M0
- IV - Any M1
For each stage, the prognoses or estimated 5-year survival rates, in the United States are as follows:
- Stage IA - 75%
- Stage IB - 55%
- Stage IIA - 50%
- Stage IIB - 40%
- Stage IIIA - 10-35% (Stage IIIA lesions have a poor prognosis, but they are technically resectable.)
- Stage IIIB - 5% (Stage IIIB lesions are nonresectable.)
- Stage IV - Less than 5%
For each stage, the prognoses or estimated 5-year survival rates in Europe are as follows:
- Stage IA - 60%
- Stage IB - 38%
- Stage IIA - 34%
- Stage IIB - 24%
- Stage IIIA - 13% (Stage IIIA lesions have a poor prognosis, but they are technically resectable.)
- Stage IIIB - 5% (Stage IIIB lesions are nonresectable.)
- Stage IV - Less than 1%
Flieder et al demonstrated that primary invasive NSCLC with a tumor greater than 2.0 cm was twice as likely to be associated with nodal metastases than carcinomas less than 2.0 cm.8 Their results suggest that in lung cancer, smaller lesions may represent earlier-stage disease and a need for further subclassification by tumor size within the current International Union Against Cancer/American Joint Committee on Cancer stage I classification, with tumors less than 2 cm classified in a separate substage. This refinement may help better clarify which patients might benefit from novel adjuvant or neoadjuvant therapeutic interventions.
Methods of Staging
Staging of the primary tumor
Conventional chest radiography
Conventional chest radiographs (CXRs) usually demonstrate the size of the tumor, especially in peripheral lesions. Central tumors may be associated with atelectasis or obstructive pneumonitis. The proximal extent of central tumors is determined with bronchoscopy.
CXRs may also show a pleural effusion, direct extension into the chest wall with destruction of the ribs or vertebrae, phrenic nerve involvement with elevation of a hemidiaphragm, or mediastinal widening due to lymphadenopathy. In the absence of these signs, CXRs are unreliable in detecting invasion of the chest wall, diaphragm, or mediastinum, and CT or MRI is required to assess these conditions.
Computed tomography
Contrast-enhanced helical CT of the thorax and abdomen that includes the liver and adrenal glands is the standard radiologic investigation for staging lung cancers. The primary tumor should be measured by using lung window settings in 2 dimensions: the maximum long axis and the largest diameter perpendicular to the long axis.9,10
CT reliably depicts mediastinal invasion, provided that the tumor surrounds the major mediastinal vessels or bronchi. A tumor that abuts the mediastinum cannot be considered invasive, even if the fat plane between the mediastinum and mass is obliterated.
CT criteria for resectability include the following:
- Contact between mass and mediastinum of less than 3 cm
- Circumferential contact between the mass and aorta of less than 90°
- Presence of a fat plane between the mass and mediastinum
Criteria for nonresectability include the following:
- Involvement of the carina
- Tumor surrounding, encasing, or abutting the aorta. Main or proximal portions of the right or left pulmonary arteries, or esophagus by more than 180°
Tumors with more than 3 cm of contact and no obvious invasion may be difficult to stage. CT and MRI cannot be used to distinguish tumor invasion of mediastinal fat from inflammatory changes.
Magnetic resonance imaging
MRI is superior to CT in assessing the pericardium, heart, and great vessels. Coronal images are useful in demonstrating the extent of tumor in the subcarinal region, aortopulmonary window, and superior vena cava. However, it is limited by poorer spatial resolution, as compared with that of CT, and by cardiac and respiratory motion artifacts; however, the magnitude of these limitations has diminished with newer MRI scanners.
MRI may be used instead of CT in patients who have had previous adverse reactions to iodinated contrast media and in patients with significant renal impairment, because MRI does not require the use of intravenous enhancement with iodinated contrast media.
The overall difference in accuracy between MRI and CT is not significant. The sensitivity of CT is 63%, and that of MRI is 56%. In the distinction of T3 and T4 tumors from less extensive tumors, the specificity of CT is 84%, and that of MRI is 80%.
Positron emission tomography
The role of positron emission tomography (PET) has become more widespread in the past 5 years. It is indicated in the assessment of indeterminate pulmonary nodules and staging. Fluorodeoxyglucose (FDG)-PET is superior to CT in differentiating between malignant and benign tumors. The preoperative use of PET has led to a reduction in the number of unnecessary thoracotomies in patients considered to be operable on the basis of CT and clinical criteria. The combination of CT and PET improves radiotherapy planning and it is to be expected that combined CT-PET–guided planning devices will further refine 3-dimensional conformal radiotherapy.11,12,13,14
Staging of mediastinal lymph nodes
Hilar (N1), ipsilateral (N2), or contralateral (N3) mediastinal lymph node metastases are often present at the time of presentation. The N stage is important because it determines both the prognosis and the suitability of curative surgery. On CXRs, CT scans, and MRIs, nodal enlargement may indicate nodal involvement; however, this finding may be inaccurate. Normal-sized nodes may contain metastases, and nodes may be enlarged due to inflammatory causes although they contain no malignant cells. Furthermore, the classification of nodes and the normal range of the size of mediastinal nodes have been disputed.
On the accepted lymph node map described by the AJCC and UICC in 1997, nodes in position 10 are designated as hilar nodes. The short-axis diameter is the most reliable measurement of lymph node size on CT scans. A short-axis diameter greater than 10 mm is abnormal regardless of the nodal station.
Conventional chest radiography
Chest radiography is inferior to CT in the detection of mediastinal lymph node metastases. It has a sensitivity of only 10-30%, but its specificity of 90% is higher than that of CT.
Computed tomography
The visualization of mediastinal nodes is facilitated by the use of spiral or multisection CT, thin (5-mm) sections, the presence of mediastinal fat, and intravenously administered contrast material.
The reported sensitivity and specificity of CT in the detection of mediastinal nodes vary considerably, with ranges of 40-84% and 52-80%, respectively. This variability reflects interobserver variability and differences in the size criteria for abnormal lymph nodes, in patient populations, and in the diagnostic criterion standard. CT is more specific in populations in Europe with a low incidence of granulomatous disease than in populations in the United States, which have a high incidence of histoplasmosis; rates are 80-90% and 50-70%, respectively.
The negative predictive value of CT is about 85%; as a result, patients with normal mediastinal appearances undergo thoracotomy. Mediastinoscopy or thoracoscopy is required during biopsy of enlarged noncalcified lymph nodes before surgery is ruled out.
Magnetic resonance imaging
Like CT, MRI size criteria are used to identify nodal involvement, and these are comparable to those used at CT. However, MRI can be used to distinguish nodes from vessels without intravenous contrast enhancement. Also, direct imaging in the sagittal and coronal planes is possible; this is helpful in the assessment of the subcarinal and aortopulmonary regions.
Positron emission tomography
Unlike MRI and CT, PET does not rely on the anatomic assessment of nodes. It is primarily a metabolic imaging technique that relies on a biochemical difference between normal and neoplastic cells. Mediastinal nodes containing tumor have an increased uptake of FDG, a glucose analogue labeled with fluorine-18 (18 F), a positron emitter. Its high cost and limited availability have reduced the impact of PET in Western countries. Recent changes in regulations and reimbursement in the United States have increased the use of PET and access to PET centers.
PET is superior to CT in the assessment of mediastinal nodal metastases. In patients with N2 disease, PET had a sensitivity of 83% and a specificity of 94% compared with a sensitivity of 63% and a specificity of 73% with CT. The superiority of PET is even more marked in the assessment of hilar nodes, for which it has a 73% sensitivity and a 76% specificity, compared with an 18% sensitivity and an 86% specificity with CT.
FDG-PET enables accurate staging of regional lymph node disease in patients with stage I NSCLC. A negative PET scan in these patients suggests that mediastinoscopy is unnecessary and that thoracotomy may be performed. FDG-PET is justified as a supporting staging measure in cases presenting unclear differentiation between N2 and N3 after conventional staging.
In about 35% of cases first staged with CT, the disease is upstaged after subsequent PET, with resultant changes in management. Nevertheless, PET can produce some false-negative results. In one study, 5 of 39 patients with negative PET scans had a carcinoma, as revealed with pathologic staging. In 4 of these patients, correlation with CT findings led to the correct conclusion. Thus, PET and CT are complementary, because the visual information on CT enables anatomic discrimination between hilar and mediastinal nodes and more accurate localization of the hot spots. The sensitivity of PET combined with CT was 93%, and the specificity was 97%.
Recent studies suggest that FDG-PET is more sensitive but less specific in cases in which lymph node enlargement is present on CT scan. For patients with lymph nodes measuring 16 mm or more on CT and a negative FDG-PET result, the post-test probability for N2 disease was 21%. These patients should be scheduled for mediastinoscopy before possible thoracotomy to prevent too many unnecessary thoracotomies in this subset. However, for patients with lymph nodes measuring 10-15 mm on CT and a negative FDG-PET result, the post-test probability for N2 disease was only 5%. These patients should be scheduled for thoracotomy because the mediastinoscopy yield will be extremely low.
Staging of distant metastases
The detection of distant metastases is of crucial importance because it usually implies that curative surgical resection of the primary tumor is contraindicated. Metastases occur in about 50% of patients with NSCLC. In patients with clinical or biochemical evidence of disease elsewhere, targeted imaging of those sites is performed. These sites include the brain, which can be examined with CT or MRI, and the skeleton, which can be examined with scintigraphy. Usually, these sites are not imaged in asymptomatic patients with NSCLC.
The probability of metastases is highest for SCLC, which is 60-80% on presentation, and lowest for squamous cell cancers; the incidence increases with advancing stage. No such trend exists for cancer involving the other cell types. Adenocarcinoma tends to metastasize to the brain and adrenals early in its course.
Liver and adrenal metastases
The staging CT scan of the thorax is usually extended to include the liver (see Image 20) and adrenal glands (see Images 21-22). CT has a sensitivity of about 85% in the detection of liver metastases. Similar rates may be obtained with MRI and ultrasonography performed by experienced imagers. Ultrasonography is superior to CT in discriminating metastases from liver cysts, which account for most of the benign lesions seen on CT scans.
Liver metastases of lung cancer.
A 7-cm metastasis of lung cancer in the right adrenal gland.
Sonogram shows a 6-cm right adrenal metastasis of lung cancer.
Adrenal metastases are common and often solitary. They must be differentiated from adrenal adenomas, which occur in 1% of the adult population. Lesions smaller than 1 cm are usually benign. Metastases are usually larger than 3 cm; on nonenhanced CT scans, they have an attenuation coefficient of 10 HU or higher. Adenomas and metastases can also be distinguished by using MRI and PET.
Brain metastases
SCLC and adenocarcinoma are the most common sources of cerebral metastases (see Images 23-24).
Contrast-enhanced CT scan shows 2 enhancing cerebral metastases of lung cancer in the left cerebral hemisphere.
Image obtained in the same case as in Multimedia Image 23 shows a third cerebral metastasis of lung cancer.
MRI is superior to CT, especially in the depiction of the posterior fossa and the area adjacent to the skull base. However, the brain is not routinely imaged in asymptomatic patients with NSCLC because the incidence of silent cerebral metastases is only 2-4%.
Bone metastases
Technetium-99m (99m Tc) radionuclide bone scanning (see Images 25-26) is indicated in patients with bone pain or local tenderness. The test has a 95% sensitivity for the detection of metastases but a high false-positive rate because of degenerative disease and trauma. The assessment of these metastases require comparison of the bone scans with plain radiographs.
Isotope bone scan.
Isotope bone scan. Hot spots due to bony metastases in the right second and ninth ribs.
Spinal metastases may cause spinal cord compression. Because only about 5% of bony metastases detected with radionuclide scans are asymptomatic, routine preoperative bone scanning is not usually performed.
Lung metastases
Pulmonary metastases (see Image 27) from a primary NSCLC are uncommon on presentation, but they are present at autopsy in 20% of cases.
Pulmonary metastases from a primary bronchial neoplasm in the left lower lobe.
Accurate preoperative diagnosis of small lung nodules depicted on CT scans is often difficult because they may be indistinguishable from granulomata and fibrotic nodules.
Positron emission tomography
In a recent study using PET, FDG uptake was increased in 92% of proven adrenal metastases (23 of 25 patients) and was normal in the 8 benign lesions. Whole-body PET will probably decrease the number of adrenal biopsies performed for indeterminate adrenal lesions. In another study, unsuspected distant metastases were found in 11% of patients with primary lung carcinoma.
Whole-body PET is more accurate than thoracic CT, bone scintigraphy, or brain CT or MRI in staging bronchogenic carcinoma. FDG-PET results have prognostic value and are strongly correlated with survival rates in patients who undergo treatment for lung cancer. Patients with positive FDG-PET results have a significantly worse prognosis than patients with negative results. Additionally, FDG-PET may be helpful in guiding treatment.
Use of combined positron emission tomography (PET) and computed tomography (CT) in lung cancer staging. The central image is the result of combining the CT (left) and PET (right) images. Courtesy of Rambam Medical Center, Haifa, Israel and GE Medical Systems.
The recent introduction of combined PET-CT machines (see Image 28) will affect the future workup and treatment of patients with cancer. These machines will also be used in radiation treatment planning. Integrated PET-CT improves the diagnostic accuracy of the staging of non–small-cell lung cancer. In a study by Lardinois et al, integrated PET-CT provided additional information in 20 (41%) of 49 patients beyond that provided by conventional visual correlation of PET and CT.15 Tumor staging and node staging were significantly more accurate with integrated PET-CT than with CT alone, PET alone, or visual correlation of PET and CT; in metastasis staging, integrated PET-CT increased the diagnostic certainty in 2 of 8 patients.
Staging of SCLC
SCLC has usually metastasized by the time of presentation. Extensive disease is present in more than 60% of patients. Surgery is an option in fewer than 5% of these patients, who have a small primary and no evidence of spread. Systemic chemotherapy is the main treatment, with response rates of 70% but cure rates of less than 5%.
The distinction between limited and extensive disease is an important staging issue. The TNM system may be applied, but it is not directly relevant to management decisions. The objectives of staging in SCLC are to identify localized disease, for which radiation therapy may be suitable, and to quantify the extent of the disease before therapy.
Localized disease is defined as disease confined to 1 hemithorax that includes ipsilateral, contralateral, and/or supraclavicular nodes. Investigations include chest radiography; CT of the thorax, liver, and adrenal glands; cranial CT; bone scintigraphy; and bone marrow aspiration. The disseminated nature of SCLC makes whole-body survey techniques suitable for its evaluation.99m Tc-labeled monoclonal antibody fragment NR-LU-10 is used to detect an antigen present in most small cell cancers. Whole-body FDG-PET is a promising technique for detecting nodal disease. Combined MRI of the brain, spine, abdomen, and pelvis enables comprehensive staging with a single modality.
Medical/Legal Pitfalls
The failure to diagnose lung cancer or a delayed diagnosis of a suspected lung cancer on a CXR is a pitfall. Any abnormality should be compared by using any previous CXRs.
The failure to accurately stage disease by using CT is a pitfall, as is the failure to diagnose metastases of the primary lung tumor.
Diagnosis of spinal cord compression is most critical. Any delay longer than 24-48 hours can result in irreversible paraplegia.
Multimedia
 | Media file 1: Image of a 1.8-cm peripheral carcinoma in the lingula, stage T1. |
 | Media file 2: Right middle lobe peripheral carcinoma, 3.5 cm in diameter, stage T2. |
 | Media file 3: Spiculated right upper lobe carcinoma, 4.2 cm in diameter, stage T2. |
 | Media file 4: Image obtained in the same case as in Image 3. Note the enlarged pretracheal lymph node, stage T2N2. |
 | Media file 5: Right apical carcinoma, stage T3. |
 | Media file 6: Image obtained in the same case as in Image 5. No rib or vertebral destruction is present. The stage is T3. |
 | Media file 7: Image obtained in the same case as in Image 5. Note the enlarged pretracheal lymph node. The stage is T3N2. |
 | Media file 8: Left upper lobe carcinoma adjacent to main pulmonary artery. A clear fat plane is present between them. |
 | Media file 9: Left hilar carcinoma with distal consolidation in the left upper lobe, stage T3, and lymphadenopathy, stage N2. |
 | Media file 10: More caudal section than that in Image 9 shows precarinal lymphadenopathy, stage N2. |
 | Media file 11: Left lower lobe atelectasis (collapse) due to carcinoma in the left lower lobe bronchus. The tumor extends along the left main bronchus to the carina. Subcarinal lymphadenopathy compresses the esophagus. |
 | Media file 12: Image obtained in the same case as in Image 11. More cephalic section shows precarinal and subcarinal lymphadenopathy. |
 | Media file 13: The left hilar tumor extends to the carina, invades the left pulmonary artery, and is contiguous with the descending aorta over an arc of greater than 180° the stage is T4. The primary tumor is difficult to separate from the mediastinal lymphadenopathy (stage Nx) and from the distal atelectasis and pneumonitis. |
 | Media file 14: More cephalic section than that in Image 13. The left main and upper lobe bronchi are narrowed, and the left upper lobe is collapsed. |
 | Media file 15: More cephalic section than that in Image 14 shows left paratracheal lymphadenopathy. |
 | Media file 16: Right hilar mass invading the mediastinum, stage T4, with mediastinal lymphadenopathy, N3 (see Images 16-19 in Multimedia). |
 | Media file 17: Subcarinal lymphadenopathy. Image was obtained in the same case as in Image 16. |
 | Media file 18: Precarinal lymphadenopathy. Image was obtained in the same case as in Image 16. |
 | Media file 19: Enlarged lymph nodes are present on both sides of the mediastinum, as well as anterior to the trachea, in this case of lung cancer. The stage is N3. Image was obtained in the same case as in Image 16. |
 | Media file 20: Liver metastases of lung cancer. |
 | Media file 21: A 7-cm metastasis of lung cancer in the right adrenal gland. |
 | Media file 22: Sonogram shows a 6-cm right adrenal metastasis of lung cancer. |
 | Media file 23: Contrast-enhanced CT scan shows 2 enhancing cerebral metastases of lung cancer in the left cerebral hemisphere. |
 | Media file 24: Image obtained in the same case as in Multimedia Image 23 shows a third cerebral metastasis of lung cancer. |
 | Media file 25: Isotope bone scan. |
 | Media file 26: Isotope bone scan. Hot spots due to bony metastases in the right second and ninth ribs. |
 | Media file 27: Pulmonary metastases from a primary bronchial neoplasm in the left lower lobe. |
 | Media file 28: Use of combined positron emission tomography (PET) and computed tomography (CT) in lung cancer staging. The central image is the result of combining the CT (left) and PET (right) images. Courtesy of Rambam Medical Center, Haifa, Israel and GE Medical Systems. |
Keywords
lung cancer staging, staging of pulmonary carcinoma, staging of bronchial carcinoma, American Joint Committee for Cancer Staging, AJCC, TNM staging, non–small cell lung cancer, NSCLC, adenocarcinoma, squamous cell carcinoma, large cell carcinoma
More on Lung Cancer, Staging |
| References |
| Further Reading |
References
Hazelton TR, Coppage L. Imaging for lung cancer restaging. Semin Roentgenol. Apr 2005;40(2):182-92. [Medline].
Munden RF, Bruzzi J. Imaging of non-small cell lung cancer. Radiol Clin North Am. May 2005;43(3):467-80, vii. [Medline].
Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. Sep 1 2005;172(5):523-9. [Medline].
Ignatius Ou SH, Zell JA. The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition. J Thorac Oncol. Mar 2009;4(3):300-310. [Medline].
Carvalho L, Cardoso E, Nunes H, Baptista V, Gomes A, Couceiro P. The IASLC lung cancer staging project. Comparing the current 6(th) TNM edition with the proposed 7(th) edition. Rev Port Pneumol. Jan/Fev 2009;15(1):67-76. [Medline].
Sobin LH, Wittekind C. International Union against Cancer; TNM: Classification of Malignant Tumors. 6th ed. New York, NY: Wiley-Liss; 2002.
Greene FL. American Joint Committee on Cancer, American Cancer Society, AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag; 2002.
Flieder DB, Port JL, Korst RJ, Christos PJ, Levin MA, Becker DE. Tumor size is a determinant of stage distribution in t1 non-small cell lung cancer. Chest. Oct 2005;128(4):2304-8. [Medline].
Henschke CI,. CT screening for lung cancer: update 2005. Surg Oncol Clin N Am. Oct 2005;14(4):761-76. [Medline].
Laurent F, Montaudon M, Corneloup O. CT and MRI of Lung Cancer. Respiration. 2006;73(2):133-42. [Medline].
Hoekstra CJ, Stroobants SG, Smit EF. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005/11;23(33):8362-70.
Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer. Jan 12 2009;[Medline].
De Wever W, Stroobants S, Coolen J, Verschakelen JA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J. Jan 2009;33(1):201-12. [Medline].
Joshi SC, Pant I, Hamzah F, Kumar G, Shukla AN. Integrated positron emission tomography/computed tomography fusion imaging: An emerging gold standard in lung cancer. Indian J Cancer. Oct-Dec 2008;45(4):137-41. [Medline].
Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. Jun 19 2003;348(25):2500-7. [Medline].
Abrams J, Doyle LA, Aisner J. Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol. Jun 1988;15(3):261-77. [Medline].
Albes JM, Dohmen BM, Schott U, et al. Value of positron emission tomography for lung cancer staging. Eur J Surg Oncol. Feb 2002;28(1):55-62. [Medline].
Boiselle PM, Patz EF Jr, Vining DJ, et al. Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Radiographics. Sep-Oct 1998;18(5):1061-9. [Medline].
Dunnick NR, Korobkin M, Francis I. Adrenal radiology: distinguishing benign from malignant adrenal masses. AJR Am J Roentgenol. Oct 1996;167(4):861-7. [Medline].
Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. May 1997;168(5):1357-60. [Medline].
Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. Jun 2000;215(3):886-90. [Medline].
Fraser RS, Muller NL, Colman N, Pare RD. Fraser & Pare's Diagnosis of Diseases of the Chest. 4th ed. Philadelphia, Pa: WB Saunders;. 1999.
Glazer HS, Duncan-Meyer J, Aronberg DJ, et al. Pleural and chest wall invasion in bronchogenic carcinoma: CT evaluation. Radiology. Oct 1985;157(1):191-4. [Medline].
Glazer HS, Kaiser LR, Anderson DJ, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology. Oct 1989;173(1):37-42. [Medline].
Greene FL, Sobin LH. The TNM system: our language for cancer care. J Surg Oncol. Jul 2002;80(3):119-20. [Medline].
Herman SJ, Winton TL, Weisbrod GL, et al. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. Mar 1994;190(3):841-6. [Medline].
Ingram CE, Belli AM, Lewars MD, et al. Normal lymph node size in the mediastinum: a retrospective study in two patient groups. Clin Radiol. Jan 1989;40(1):35-9. [Medline].
Keogan MT, Tung KT, Kaplan DK, et al. The significance of pulmonary nodules detected on CT staging for lung cancer. Clin Radiol. Aug 1993;48(2):94-6. [Medline].
Keppler JS, Conti PS. A cost analysis of positron emission tomography. AJR Am J Roentgenol. Jul 2001;177(1):31-40. [Medline].
Kuriyama K, Tateishi R, Kumatani T, et al. Pleural invasion by peripheral bronchogenic carcinoma: assessment with three-dimensional helical CT. Radiology. May 1994;191(2):365-9. [Medline].
Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. Nov 5 1994;344(8932):1265-6. [Medline].
Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. Sep 1999;212(3):803-9. [Medline].
McLoud TC. CT of bronchogenic carcinoma: indeterminate mediastinal invasion. Radiology. Oct 1989;173(1):15-6. [Medline].
McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. Feb 1992;182(2):319-23. [Medline].
Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. Jun 1997;111(6):1710-7. [Medline].
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. Jun 1997;111(6):1718-23. [Medline].
Musset D, Grenier P, Carette MF, et al. Primary lung cancer staging: prospective comparative study of MR imaging with CT. Radiology. Sep 1986;160(3):607-11. [Medline].
Ohno Y, Sugimura K, Hatabu H. MR imaging of lung cancer. Eur J Radiol. Dec 2002;44(3):172-81.
Ollenberger GP. Staging of lung cancer with integrated PET-CT. N Engl J Med. Jan 1 2004;350(1):86-7; author reply 86-7. [Medline].
Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non- small cell lung cancer. AJR Am J Roentgenol. Mar 2000;174(3):769-74. [Medline].
Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. Dec 1995;108(6):1617-21. [Medline].
Peto R, Lopez AD, Boreham J, et al. Mortality from smoking worldwide. Br Med Bull. Jan 1996;52(1):12-21. [Medline].
Scott IR, Muller NL, Miller RR, et al. Resectable stage III lung cancer: CT, surgical, and pathologic correlation. Radiology. Jan 1988;166(1 Pt 1):75-9. [Medline].
Stiglbauer R, Schurawitzki H, Klepetko W, et al. Contrast-enhanced MRI for the staging of bronchogenic carcinoma: comparison with CT and histopathologic staging--preliminary results. Clin Radiol. Nov 1991;44(5):293-8. [Medline].
Suzuki N, Saitoh T, Kitamura S. Tumor invasion of the chest wall in lung cancer: diagnosis with US. Radiology. Apr 1993;187(1):39-42. [Medline].
Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer. Jun 15 1996;77(12):2464-70. [Medline].
Vansteenkiste JF, Stroobants SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am. Feb 2004;18(1):269-88. [Medline].
Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest. Dec 1997;112(6):1480-6. [Medline].
White PG, Adams H, Crane MD, Butchart EG. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumours?. Thorax. Oct 1994;49(10):951-7. [Medline].
Further Reading
Related eMedicine topics
Lung Cancer, Oat Cell (Small Cell)
Lung Cancer, Small Cell
Lung Cancer, Non-Small Cell (from Radiology)
Lung Cancer, Non-Small Cell (from Oncology)
Lung, Carcinoid
Clinical guidelines
Management of Patients with Lung Cancer: A National Clinical Guideline
The Diagnosis and Treatment of Lung Cancer
Clinical trials
FR901228 in Treating Patients with Refractory or Progressive Small Cell Lung Cancer or Non-Small Cell Lung Cancer
Prevention of Tumor Spread Due to Lung Cancer Surgery
Keywords
lung cancer staging, staging of pulmonary carcinoma, staging of bronchial carcinoma, American Joint Committee for Cancer Staging, AJCC, TNM staging, non–small cell lung cancer, NSCLC, adenocarcinoma, squamous cell carcinoma, large cell carcinoma
